IL104166A - Polymers and oligomers of bile acid derivatives process for their preparation and their use as pharmaceuticals - Google Patents

Polymers and oligomers of bile acid derivatives process for their preparation and their use as pharmaceuticals

Info

Publication number: IL104166A
Authority: IL; Israel
Prior art keywords: alkyl; group; esters; formula; ethylenically unsaturated
Prior art date: 1991-12-20

Application number

IL10416692A

Other languages

English (en)

Other versions

IL104166A0 (en

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-20

Filing date

1992-12-18

Publication date

1999-04-11

1992-12-18 Application filed by Hoechst Ag filed Critical Hoechst Ag

1993-05-13 Publication of IL104166A0 publication Critical patent/IL104166A0/xx

1999-04-11 Publication of IL104166A publication Critical patent/IL104166A/en

Links

239000003814 drug Substances 0.000 title claims abstract description 11
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title claims description 27
238000000034 method Methods 0.000 title claims description 21
230000008569 process Effects 0.000 title claims description 19
229920000642 polymer Polymers 0.000 title claims description 16
238000002360 preparation method Methods 0.000 title claims description 10
239000003613 bile acid Substances 0.000 claims abstract description 56
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 19
150000002148 esters Chemical class 0.000 claims abstract description 19
239000000178 monomer Substances 0.000 claims abstract description 17
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 10
150000001991 dicarboxylic acids Chemical class 0.000 claims abstract description 5
150000008064 anhydrides Chemical class 0.000 claims abstract description 4
125000005907 alkyl ester group Chemical group 0.000 claims abstract description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 3
125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 3
239000003599 detergent Substances 0.000 claims abstract description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
-1 alkali metal salt Chemical class 0.000 claims description 24
150000001875 compounds Chemical class 0.000 claims description 24
229910052739 hydrogen Inorganic materials 0.000 claims description 19
239000001257 hydrogen Substances 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 16
239000000126 substance Substances 0.000 claims description 16
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 15
238000007334 copolymerization reaction Methods 0.000 claims description 12
150000003254 radicals Chemical class 0.000 claims description 11
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
239000002904 solvent Substances 0.000 claims description 9
229910052783 alkali metal Inorganic materials 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
125000002947 alkylene group Chemical group 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
239000003999 initiator Substances 0.000 claims description 5
238000006116 polymerization reaction Methods 0.000 claims description 5
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 4
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
239000002585 base Substances 0.000 claims description 4
229920001577 copolymer Polymers 0.000 claims description 4
150000002431 hydrogen Chemical class 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
150000001408 amides Chemical class 0.000 claims description 3
125000006239 protecting group Chemical group 0.000 claims description 3
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical class OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
239000000460 chlorine Substances 0.000 claims description 2
125000004185 ester group Chemical group 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
150000007522 mineralic acids Chemical class 0.000 claims description 2
150000007524 organic acids Chemical class 0.000 claims description 2
235000005985 organic acids Nutrition 0.000 claims description 2
239000000725 suspension Substances 0.000 claims description 2
238000004132 cross linking Methods 0.000 claims 3
239000000654 additive Substances 0.000 claims 1
238000009472 formulation Methods 0.000 claims 1
229910052740 iodine Inorganic materials 0.000 claims 1
150000005690 diesters Chemical class 0.000 abstract 1
239000002778 food additive Substances 0.000 abstract 1
235000013373 food additive Nutrition 0.000 abstract 1
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 66
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
239000011541 reaction mixture Substances 0.000 description 37
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
239000000243 solution Substances 0.000 description 19
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 13
235000019400 benzoyl peroxide Nutrition 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 13
238000003756 stirring Methods 0.000 description 11
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
239000008367 deionised water Substances 0.000 description 9
229910021641 deionized water Inorganic materials 0.000 description 9
230000010235 enterohepatic circulation Effects 0.000 description 9
229910052757 nitrogen Inorganic materials 0.000 description 9
210000000941 bile Anatomy 0.000 description 8
239000000047 product Substances 0.000 description 8
210000000813 small intestine Anatomy 0.000 description 8
230000000694 effects Effects 0.000 description 7
210000000936 intestine Anatomy 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
230000000968 intestinal effect Effects 0.000 description 6
239000000700 radioactive tracer Substances 0.000 description 6
239000011347 resin Substances 0.000 description 6
229920005989 resin Polymers 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 5
WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
230000009102 absorption Effects 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
239000003431 cross linking reagent Substances 0.000 description 4
239000003480 eluent Substances 0.000 description 4
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
230000035484 reaction time Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
229920001268 Cholestyramine Polymers 0.000 description 3
229920002911 Colestipol Polymers 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 3
229960002604 colestipol Drugs 0.000 description 3
229960001678 colestyramine Drugs 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
210000003405 ileum Anatomy 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000011835 investigation Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000009103 reabsorption Effects 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
208000000412 Avitaminosis Diseases 0.000 description 2
206010010774 Constipation Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000031200 bile acid secretion Effects 0.000 description 2
210000000013 bile duct Anatomy 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000003312 cholesterol blood level Effects 0.000 description 2
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229940015043 glyoxal Drugs 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
239000013580 millipore water Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000002572 peristaltic effect Effects 0.000 description 2
238000010526 radical polymerization reaction Methods 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
KXYJPVZMZBJJBZ-UHFFFAOYSA-N tert-butyl 2-ethylbutaneperoxoate Chemical compound CCC(CC)C(=O)OOC(C)(C)C KXYJPVZMZBJJBZ-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000032258 transport Effects 0.000 description 2
ZICNIEOYWVIEQJ-UHFFFAOYSA-N (2-methylbenzoyl) 2-methylbenzenecarboperoxoate Chemical compound CC1=CC=CC=C1C(=O)OOC(=O)C1=CC=CC=C1C ZICNIEOYWVIEQJ-UHFFFAOYSA-N 0.000 description 1
HGXJDMCMYLEZMJ-UHFFFAOYSA-N (2-methylpropan-2-yl)oxy 2,2-dimethylpropaneperoxoate Chemical compound CC(C)(C)OOOC(=O)C(C)(C)C HGXJDMCMYLEZMJ-UHFFFAOYSA-N 0.000 description 1
KDGNCLDCOVTOCS-UHFFFAOYSA-N (2-methylpropan-2-yl)oxy propan-2-yl carbonate Chemical compound CC(C)OC(=O)OOC(C)(C)C KDGNCLDCOVTOCS-UHFFFAOYSA-N 0.000 description 1
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
UBRWPVTUQDJKCC-UHFFFAOYSA-N 1,3-bis(2-tert-butylperoxypropan-2-yl)benzene Chemical compound CC(C)(C)OOC(C)(C)C1=CC=CC(C(C)(C)OOC(C)(C)C)=C1 UBRWPVTUQDJKCC-UHFFFAOYSA-N 0.000 description 1
GAGSKMIUFQWLGN-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxy]ethyl hexanoate Chemical compound CCCCCC(=O)OC(C)OC(C)(C)C GAGSKMIUFQWLGN-UHFFFAOYSA-N 0.000 description 1
LGJCFVYMIJLQJO-UHFFFAOYSA-N 1-dodecylperoxydodecane Chemical compound CCCCCCCCCCCCOOCCCCCCCCCCCC LGJCFVYMIJLQJO-UHFFFAOYSA-N 0.000 description 1
GOAHRBQLKIZLKG-UHFFFAOYSA-N 1-tert-butylperoxybutane Chemical compound CCCCOOC(C)(C)C GOAHRBQLKIZLKG-UHFFFAOYSA-N 0.000 description 1
DMWVYCCGCQPJEA-UHFFFAOYSA-N 2,5-bis(tert-butylperoxy)-2,5-dimethylhexane Chemical compound CC(C)(C)OOC(C)(C)CCC(C)(C)OOC(C)(C)C DMWVYCCGCQPJEA-UHFFFAOYSA-N 0.000 description 1
XMNIXWIUMCBBBL-UHFFFAOYSA-N 2-(2-phenylpropan-2-ylperoxy)propan-2-ylbenzene Chemical compound C=1C=CC=CC=1C(C)(C)OOC(C)(C)C1=CC=CC=C1 XMNIXWIUMCBBBL-UHFFFAOYSA-N 0.000 description 1
KRDXTHSSNCTAGY-UHFFFAOYSA-N 2-cyclohexylpyrrolidine Chemical compound C1CCNC1C1CCCCC1 KRDXTHSSNCTAGY-UHFFFAOYSA-N 0.000 description 1
ZACVGCNKGYYQHA-UHFFFAOYSA-N 2-ethylhexoxycarbonyloxy 2-ethylhexyl carbonate Chemical compound CCCCC(CC)COC(=O)OOC(=O)OCC(CC)CCCC ZACVGCNKGYYQHA-UHFFFAOYSA-N 0.000 description 1
RAWISQFSQWIXCW-UHFFFAOYSA-N 2-methylbutan-2-yl 2,2-dimethyloctaneperoxoate Chemical compound CCCCCCC(C)(C)C(=O)OOC(C)(C)CC RAWISQFSQWIXCW-UHFFFAOYSA-N 0.000 description 1
AQKYLAIZOGOPAW-UHFFFAOYSA-N 2-methylbutan-2-yl 2,2-dimethylpropaneperoxoate Chemical compound CCC(C)(C)OOC(=O)C(C)(C)C AQKYLAIZOGOPAW-UHFFFAOYSA-N 0.000 description 1
SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
AVXWWBFBRTXBRM-UHFFFAOYSA-N 3-bromopyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=C1Br AVXWWBFBRTXBRM-UHFFFAOYSA-N 0.000 description 1
CARSMBZECAABMO-UHFFFAOYSA-N 3-chloro-2,6-dimethylbenzoic acid Chemical compound CC1=CC=C(Cl)C(C)=C1C(O)=O CARSMBZECAABMO-UHFFFAOYSA-N 0.000 description 1
101710172561 3alpha-hydroxysteroid dehydrogenase Proteins 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102100024089 Aldo-keto reductase family 1 member C2 Human genes 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
208000025814 Inflammatory myopathy with abundant macrophages Diseases 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
238000008214 LDL Cholesterol Methods 0.000 description 1
102000000853 LDL receptors Human genes 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000019280 Pancreatic lipases Human genes 0.000 description 1
108050006759 Pancreatic lipases Proteins 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010041969 Steatorrhoea Diseases 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
150000003926 acrylamides Chemical class 0.000 description 1
230000009056 active transport Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
BVCZEBOGSOYJJT-UHFFFAOYSA-N ammonium carbamate Chemical compound [NH4+].NC([O-])=O BVCZEBOGSOYJJT-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000005840 aryl radicals Chemical class 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
NSGQRLUGQNBHLD-UHFFFAOYSA-N butan-2-yl butan-2-yloxycarbonyloxy carbonate Chemical compound CCC(C)OC(=O)OOC(=O)OC(C)CC NSGQRLUGQNBHLD-UHFFFAOYSA-N 0.000 description 1
ZGPBOPXFOJBLIV-UHFFFAOYSA-N butoxycarbonyloxy butyl carbonate Chemical compound CCCCOC(=O)OOC(=O)OCCCC ZGPBOPXFOJBLIV-UHFFFAOYSA-N 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
229960001091 chenodeoxycholic acid Drugs 0.000 description 1
229940099352 cholate Drugs 0.000 description 1
201000001883 cholelithiasis Diseases 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
238000013016 damping Methods 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
238000013461 design Methods 0.000 description 1
LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001917 fluorescence detection Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
150000005826 halohydrocarbons Chemical class 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
150000001451 organic peroxides Chemical class 0.000 description 1
230000009057 passive transport Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
229960003912 probucol Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
BWJUFXUULUEGMA-UHFFFAOYSA-N propan-2-yl propan-2-yloxycarbonyloxy carbonate Chemical compound CC(C)OC(=O)OOC(=O)OC(C)C BWJUFXUULUEGMA-UHFFFAOYSA-N 0.000 description 1
238000002271 resection Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
208000001162 steatorrhea Diseases 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
PFBLRDXPNUJYJM-UHFFFAOYSA-N tert-butyl 2-methylpropaneperoxoate Chemical class CC(C)C(=O)OOC(C)(C)C PFBLRDXPNUJYJM-UHFFFAOYSA-N 0.000 description 1
NMOALOSNPWTWRH-UHFFFAOYSA-N tert-butyl 7,7-dimethyloctaneperoxoate Chemical compound CC(C)(C)CCCCCC(=O)OOC(C)(C)C NMOALOSNPWTWRH-UHFFFAOYSA-N 0.000 description 1
GJBRNHKUVLOCEB-UHFFFAOYSA-N tert-butyl benzenecarboperoxoate Chemical compound CC(C)(C)OOC(=O)C1=CC=CC=C1 GJBRNHKUVLOCEB-UHFFFAOYSA-N 0.000 description 1
SWAXTRYEYUTSAP-UHFFFAOYSA-N tert-butyl ethaneperoxoate Chemical class CC(=O)OOC(C)(C)C SWAXTRYEYUTSAP-UHFFFAOYSA-N 0.000 description 1
125000001302 tertiary amino group Chemical group 0.000 description 1
239000012085 test solution Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229920001567 vinyl ester resin Polymers 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000003643 water by type Substances 0.000 description 1
238000004260 weight control Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F12/02—Monomers containing only one unsaturated aliphatic radical
- C08F12/04—Monomers containing only one unsaturated aliphatic radical containing one ring
- C08F12/14—Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing heteroatoms
- C08F12/26—Nitrogen
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
- C08F20/52—Amides or imides
- C08F20/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Polymers & Plastics (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicinal Preparation (AREA)
Detergent Compositions (AREA)
Cephalosporin Compounds (AREA)
Lubricants (AREA)
Polyesters Or Polycarbonates (AREA)

IL10416692A 1991-12-20 1992-12-18 Polymers and oligomers of bile acid derivatives process for their preparation and their use as pharmaceuticals IL104166A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4142379		1991-12-20

Publications (2)

Publication Number	Publication Date
IL104166A0 IL104166A0 (en)	1993-05-13
IL104166A true IL104166A (en)	1999-04-11

Family

ID=6447759

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10416692A IL104166A (en)	1991-12-20	1992-12-18	Polymers and oligomers of bile acid derivatives process for their preparation and their use as pharmaceuticals

Country Status (17)

Country	Link
US (1)	US5430116A (ja)
EP (1)	EP0549967B1 (ja)
JP (1)	JP3292318B2 (ja)
AT (1)	ATE135380T1 (ja)
AU (1)	AU653658B2 (ja)
CA (1)	CA2085831C (ja)
DE (1)	DE59205695D1 (ja)
DK (1)	DK0549967T3 (ja)
ES (1)	ES2087422T3 (ja)
FI (1)	FI108451B (ja)
GR (1)	GR3019564T3 (ja)
HU (1)	HUT63434A (ja)
IL (1)	IL104166A (ja)
NO (1)	NO301889B1 (ja)
NZ (1)	NZ245503A (ja)
TW (1)	TW255898B (ja)
ZA (1)	ZA929827B (ja)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ245504A (en) *	1991-12-20	1995-08-28	Hoechst Ag	Bile acid derivatives containing an ethylenically unsaturated grouping
ATE156911T1 (de) *	1994-03-04	1997-08-15	Waters Investments Ltd	Verfahren zum nachweis von polymeren in einer lösung, detektorsystem und eine ein solches detektorsystem beinhaltende chromatographievorrichtung
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5994391A (en) *	1994-09-13	1999-11-30	G.D. Searle And Company	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en)	1994-09-13	2001-07-31	G. D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en) *	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6107494A (en) *	1994-09-13	2000-08-22	G.D. Searle And Company	Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE19633268A1 (de) *	1996-08-19	1998-02-26	Hoechst Ag	Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung
PL336415A1 (en) *	1997-03-11	2000-06-19	Searle & Co	Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors
KR100313150B1 (ko) *	1997-12-31	2001-12-28	박종섭	리소콜릴에시딜(메타)아크릴레이트 단량체와 그를 도입한 공중합체 수지 및 이 수지를 이용한 포토레지스트
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
JP2002533412A (ja)	1998-12-23	2002-10-08	ジー．ディー．サールエルエルシー	心臓血管に適用するための回腸胆汁酸輸送阻害剤およびコレステリルエステル転送タンパク質阻害剤の組み合わせ
KR20020002367A (ko) *	1998-12-23	2002-01-09	윌리암스 로저 에이	심혈관 징후를 위한 조합물
WO2000038721A1 (en) *	1998-12-23	2000-07-06	G.D. Searle Llc	Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
WO2000038727A1 (en) *	1998-12-23	2000-07-06	G.D. Searle Llc	Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
PT1140185E (pt)	1998-12-23	2003-10-31	Searle Llc	Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com agentes sequestrantes de acido biliar para indicacoes cardiovasculares
AU2157400A (en)	1998-12-23	2000-07-31	G.D. Searle & Co.	Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
PL348503A1 (en) *	1998-12-23	2002-05-20	Searle Llc	Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
PT1140190E (pt)	1998-12-23	2003-02-28	Searle Llc	Combinacoes de inibidores do transporte ileal dos acidos biliares e agentes sequestrantes dos acidos biliares usadas para problemas cardiovasculares
US6586434B2 (en)	2000-03-10	2003-07-01	G.D. Searle, Llc	Method for the preparation of tetrahydrobenzothiepines
WO2001068096A2 (en) *	2000-03-10	2001-09-20	Pharmacia Corporation	Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
SE0003766D0 (sv) *	2000-10-18	2000-10-18	Astrazeneca Ab	Novel formulation
US20040077625A1 (en) *	2001-07-25	2004-04-22	Tremont Samuel J.	Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
BR0213501A (pt)	2001-11-02	2004-08-24	Searle Llc	Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
US6852753B2 (en)	2002-01-17	2005-02-08	Pharmacia Corporation	Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
ES2552657T3 (es)	2010-05-26	2015-12-01	Satiogen Pharmaceuticals, Inc.	Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
ES2687027T3 (es)	2010-11-04	2018-10-23	Albireo Ab	Inhibidores de ibat para el tratamiento de enfermedades hepáticas
DK2637646T3 (en)	2010-11-08	2016-08-29	Albireo Ab	PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
AU2012328526B2 (en)	2011-10-28	2017-05-25	Shire Human Genetic Therapies, Inc.	Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US20130108573A1 (en)	2011-10-28	2013-05-02	Lumena Pharmaceuticals, Inc.	Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2014229050A1 (en)	2013-03-15	2015-10-22	Lumena Pharmaceuticals Llc	Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
CA2907230A1 (en)	2013-03-15	2014-09-18	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar)	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh)	2014-06-25	2017-05-10	Ea制药株式会社	固体制剂及其着色防止或着色减少方法
EP3197459B1 (en) *	2014-09-28	2025-02-12	Huahui Health Ltd.	Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport
EP3012252A1 (en)	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
WO2017138878A1 (en)	2016-02-09	2017-08-17	Albireo Ab	Oral cholestyramine formulation and use thereof
ES2874669T3 (es)	2016-02-09	2021-11-05	Albireo Ab	Formulación oral de colestiramina y uso de la misma
CN108601739B (zh)	2016-02-09	2022-01-04	阿尔比里奥公司	考来烯胺丸剂及其制备方法
EP3664782B1 (en)	2017-08-09	2025-01-29	Albireo AB	Cholestyramine pellets, oral cholestyramine formulations and medical use thereof
CN111032019B (zh)	2017-08-09	2022-07-05	阿尔比里奥公司	考来烯胺颗粒、口服考来烯胺制剂及其用途
CN112449637B (zh)	2018-06-05	2024-03-19	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
PL3810581T3 (pl)	2018-06-20	2025-04-28	Albireo Ab	Modyfikacje kryształu odewiksibatu
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
TWI835997B (zh)	2019-02-06	2024-03-21	瑞典商艾爾比瑞歐公司	苯并噻氮呯化合物及其用作膽酸調節劑之用途
CN118852054A (zh)	2019-02-06	2024-10-29	阿尔比里奥公司	苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
EP3923943B1 (en)	2019-02-12	2024-07-31	Mirum Pharmaceuticals, Inc.	Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
TWI877263B (zh)	2019-12-04	2025-03-21	瑞典商艾爾比瑞歐公司	苯并噻二氮呯化合物及其作為膽酸調節劑之用途
JP7696898B2 (ja)	2019-12-04	2025-06-23	アルビレオ・アクチボラグ	ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11014898B1 (en)	2020-12-04	2021-05-25	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
WO2021110887A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
IL293379B2 (en)	2019-12-04	2026-04-01	Albireo Ab	Benzothia(dia)azepine compounds and their use as bile acid modulators
EP4069247B1 (en)	2019-12-04	2025-03-26	Albireo AB	Benzothiadiazepine compounds and their use as bile acid modulators
WO2021110883A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110884A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
AR120676A1 (es)	2019-12-04	2022-03-09	Albireo Ab	Compuestos de benzoti(di)azepina y su uso como ácido biliar
ES2973355T3 (es)	2019-12-04	2024-06-19	Albireo Ab	Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
EP4188541B1 (en)	2020-08-03	2024-12-25	Albireo AB	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en)	2020-08-03	2022-02-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en)	2020-11-12	2022-05-19	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt)	2020-12-04	2023-10-03	Albireo Ab	Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
TW202313579A (zh)	2021-06-03	2023-04-01	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
KR20250022025A (ko)	2022-06-09	2025-02-14	알비레오 에이비	간염 치료
CN119487013A (zh)	2022-07-05	2025-02-18	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AU2023390975A1 (en)	2022-12-09	2025-06-05	Albireo Ab	Asbt inhibitors in the treatment of renal diseases
WO2025146508A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3383281A (en) *	1961-09-22	1968-05-14	Merck & Co Inc	Method for binding bile acids in vivo
US3709867A (en) *	1971-11-22	1973-01-09	Owens Illinois Inc	Process for lubricating vinyl polymers with sitosterol compounds and stabilized product thereof
SU525709A1 (ru) *	1975-03-10	1976-08-25	Московский Ордена Ленина И Ордена Трудового Красного Знамени Государственный Университет Имени М.В.Ломоносова	Способ получени полимеров
US4104285A (en) *	1977-04-22	1978-08-01	Hoffmann-La Roche Inc.	Taurine and glycine derivatives
DE3930696A1 (de) *	1989-09-14	1991-03-28	Hoechst Ag	Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5250524A (en) *	1990-12-06	1993-10-05	Hoechst Aktiengesellschaft	Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals

1992
- 1992-12-17 EP EP92121459A patent/EP0549967B1/de not_active Expired - Lifetime
- 1992-12-17 DE DE59205695T patent/DE59205695D1/de not_active Expired - Lifetime
- 1992-12-17 AT AT92121459T patent/ATE135380T1/de not_active IP Right Cessation
- 1992-12-17 FI FI925735A patent/FI108451B/fi active
- 1992-12-17 ES ES92121459T patent/ES2087422T3/es not_active Expired - Lifetime
- 1992-12-17 DK DK92121459.9T patent/DK0549967T3/da active
- 1992-12-17 NZ NZ245503A patent/NZ245503A/en unknown
- 1992-12-17 AU AU30209/92A patent/AU653658B2/en not_active Ceased
- 1992-12-17 US US07/992,411 patent/US5430116A/en not_active Expired - Lifetime
- 1992-12-18 HU HU9204020A patent/HUT63434A/hu unknown
- 1992-12-18 ZA ZA929827A patent/ZA929827B/xx unknown
- 1992-12-18 IL IL10416692A patent/IL104166A/en not_active IP Right Cessation
- 1992-12-18 JP JP35485792A patent/JP3292318B2/ja not_active Expired - Lifetime
- 1992-12-18 CA CA002085831A patent/CA2085831C/en not_active Expired - Lifetime
- 1992-12-18 NO NO924922A patent/NO301889B1/no not_active IP Right Cessation
- 1992-12-29 TW TW081110422A patent/TW255898B/zh active
1996
- 1996-04-05 GR GR960400949T patent/GR3019564T3/el unknown

Also Published As

Publication number	Publication date
JP3292318B2 (ja)	2002-06-17
HUT63434A (en)	1993-08-30
FI108451B (fi)	2002-01-31
IL104166A0 (en)	1993-05-13
ZA929827B (en)	1993-06-23
US5430116A (en)	1995-07-04
FI925735L (fi)	1993-06-21
AU653658B2 (en)	1994-10-06
EP0549967B1 (de)	1996-03-13
FI925735A0 (fi)	1992-12-17
TW255898B (ja)	1995-09-01
ES2087422T3 (es)	1996-07-16
NO924922L (no)	1993-06-21
DE59205695D1 (de)	1996-04-18
CA2085831C (en)	2006-05-30
NO301889B1 (no)	1997-12-22
EP0549967A1 (de)	1993-07-07
AU3020992A (en)	1993-06-24
NO924922D0 (no)	1992-12-18
NZ245503A (en)	1995-11-27
HU9204020D0 (en)	1993-04-28
JPH0625354A (ja)	1994-02-01
GR3019564T3 (en)	1996-07-31
ATE135380T1 (de)	1996-03-15
DK0549967T3 (da)	1996-07-22
CA2085831A1 (en)	1993-06-21

Legal Events

Date	Code	Title
1999-08-17	FF	Patent granted
2000-06-01	KB	Patent renewed
2003-09-17	RH1	Patent not in force

Publication	Publication Date	Title
AU653658B2 (en)	1994-10-06	Polymers and oligomers of bile acid derivatives, process for their preparation and their use as pharmaceuticals
JP2535785B2 (ja)	1996-09-18	血管塞栓剤
US6060517A (en)	2000-05-09	Process for removing bile salts from a patient and compositions therefor
Stenzel et al.	2004	Amphiphilic block copolymers based on poly (2‐acryloyloxyethyl phosphorylcholine) prepared via RAFT polymerisation as biocompatible nanocontainers
US3963685A (en)	1976-06-15	Alcohol soluble hydrophilic polymer via aqueous polymerization
Davaran et al.	1999	Release of 5-amino salicylic acid from acrylic type polymeric prodrugs designed for colon-specific drug delivery
Yoshida et al.	2003	Newly designed hydrogel with both sensitive thermoresponse and biodegradability
US9044515B2 (en)	2015-06-02	Chemical conjugates for targeted degradation under reducing conditions
CA2263671A1 (en)	1998-02-26	Polymer bile acid resorption inhibitors with simultaneous bile acid adsorbing effect
Ferruti et al.	1994	Recent results on functional polymers and macromonomers of interest as biomaterials or for biomaterial modification
Liu et al.	2001	N‐Isopropylacrylamide Copolymers with Acrylamide and Methacrylamide Derivatives of Cholic Acid: Synthesis and Characterization
US6036948A (en)	2000-03-14	Polyaspartamide derivatives as adsordents for bile acids, polyaspartamide derivatives loaded with bile acids and process for their preparation and their use as pharmaceuticals
HUT65692A (en)	1994-07-28	Process for preparing crosslinked polymeric matrix, that are capable of sequestring bile acids and pharmaceutical compositions containing them
JP3186081B2 (ja)	2001-07-11	糖応答性高分子複合体
JP2874309B2 (ja)	1999-03-24	糖応答性高分子複合体
Ranucci et al.	2000	New ester and lactone end‐functionalized N‐vinyl‐2‐pyrrolidinone oligomers
CN119638731B (zh)	2025-12-12	一种苯硼酸化合物、聚合物、胰岛素缓释制剂和应用
CA2963582C (en)	2017-12-05	Oral preparation comprising mucoadhesive, biocompatible hydrophilic polymer for preventing and/or treating inflammatory conditions of the gastrointestinal tract
CN115894826B (zh)	2025-07-15	一种具有长循环、长效抗蛋白稳定性的三嵌段聚合物及其制备与应用
JP2011072257A (ja)	2011-04-14	遺伝子導入剤及びその製造方法、並びに核酸複合体
Negru et al.	2011	Thermosensitive branched block copolymers of poly (ethylene glycol) and copolyacrylates of oligo (ethylene glycol) s: Synthesis and thermal gelation properties of aqueous solutions
Gwon et al.	2010	New route for synthesizing poly (ethylene glycol)-acrylic acid hydrogels using γ-irradiation for drug delivery carriers
Ranjha et al.	1999	PH-Sensitive Noncrosslinked Poly (Vinyl Alcohol-Co-Acrylic Acid) Hydrogels for Site Specif Drug Delivery
Valenti et al.	2016	Controlled release of cortisone drugs from block copolymers synthetized by ATRP
JPS6277331A (ja)	1987-04-09	医療用重合体カプセル